RedHill Biopharma Announces New Collaboration

TL;DR

RHBP announces a new collaboration via 6-K filing.

AI Summary

RedHill Biopharma Ltd. filed a Form 6-K on October 22, 2024, to report information as a foreign private issuer. The filing includes a press release titled "RedHill Announces Collabora", indicating a new collaboration or partnership for the company.

Why It Matters

This filing signals a potential strategic move by RedHill Biopharma, which could impact its product development, market reach, or financial performance.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the nature of the announced collaboration could introduce new risks or opportunities for RedHill Biopharma.

Key Players & Entities

• RedHill Biopharma Ltd. (company) — Registrant
• 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (location) — Principal executive offices
• October 2024 (date) — Reporting period

FAQ

Filing Documents

• zk2432165.htm (6-K) — 40KB
• image00001.jpg (GRAPHIC) — 308KB
• 0001178913-24-003353.txt ( ) — 465KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: October 22, 2024 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer 2 Press Release RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene inhalation injury. The collaboration aims to determine whether opaganib can advance into further definitive U.S. government-sponsored development under the FDA's Animal Rule pathway to approval -- Used as a chemical weapon during World War I, phosgene, a toxic, colorless chemical, is today widely used in industrial processes for the manufacture of plastics and pesticides. The U.S. Environmental Protection Agency (EPA) identified 123 sites in the United States that could potentially expose millions of people to phosgene due to plant malfunction or bioterrorism 1 -- Phosgene inhalation can be extremely dangerous, causing significant, even fatal, respiratory injury. No known approved antidote or reversal agent currently exists, and, if approved, opaganib may provide potential for stockpiling for emergency use in the event of a major public safety incident -- With multiple U.S. government collaborations for chemical and medical countermeasures and pandemic preparedness, RedHill's opaganib is a novel, host-directed, potentially broad acting, orally administered small molecule, clinical-stage drug with demonstrated safety & efficacy profiles, being developed for various oncology, viral infections, inflammatory diseases and chemical and nuclear/radioprotection indications TEL-AVIV, Israel / RAL

Forward-Looking Statements

Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include, among others, statements regarding the potential effects of opaganib in the treatment of phosgene inhalation injury. Forward-looking materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions; the Company's ability to maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication; the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-study requirements will not be met and/or that the Phase 3 study of RHB-107 in COVID-19 outpatients will not be approved to commence or if approved, will not be completed or, should that be the case, that we will not be successful in obtaining alternative non-dilutive development funding for RHB-107; the risk that RHB-107'

View Full Filing

View this 6-K filing on SEC EDGAR